Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma

Spartalizumab in combination with dabrafenib and trametinib failed to meet the primary end point of investigator-assessed progression-free survival in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma.

Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma

Spartalizumab in combination with dabrafenib and trametinib failed to meet the primary end point of investigator-assessed progression-free survival in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma.

Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma

Spartalizumab in combination with dabrafenib and trametinib failed to meet the primary end point of investigator-assessed progression-free survival in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma.

Dr. Liebman on the Use of Digital Surveillance in Melanoma

Tracey Liebman, MD, discusses the use of digital surveillance in melanoma.

Dr. Johnson on the Limitations of Biomarkers in Melanoma

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Experts Examine Emerging Approaches in Melanoma Management

A panel of experts discuss some of the encouraging data on emerging modalities in melanoma presented during the 2020 ASCO Virtual Scientific Program and share how they might apply that information to clinical practice.

Experts Examine Emerging Approaches in Melanoma Management

A panel of experts discuss some of the encouraging data on emerging modalities in melanoma presented during the 2020 ASCO Virtual Scientific Program and share how they might apply that information to clinical practice.

Experts Examine Emerging Approaches in Melanoma Management

A panel of experts discuss some of the encouraging data on emerging modalities in melanoma presented during the 2020 ASCO Virtual Scientific Program and share how they might apply that information to clinical practice.

Novel Triplet Emerges as a Promising Option in BRAF-Mutant Melanoma

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the safety profile of the combination of spartalizumab, dabrafenib, and trametinib, the clinical implications of the biomarker data observed from this trial, and other emerging combinations on the horizon.

Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma

Richard L. Shapiro, MD, discusses the utility of complete lymph node dissection in melanoma.